食管癌、贲门癌和胃癌DNA倍体分析及其临床意义  

Clinical significance of DNA ploidy of carcinoma of esophagus,gastric cardia and stomach.

作　　者：程爱明[1] 李金陵[2] 崔亚玲[1] 

机构地区：[1]河南省肿瘤研究所,郑州450008 [2]河南省医学科学研究所

出　　处：《中国医药》2006年第4期228-229,共2页China Medicine

摘　　要：目的探讨食管癌、贲门癌和胃癌患者DNA倍体的临床应用价值。方法应用流式细胞术测定100例上消化道恶性肿瘤患者癌细胞DNA含量,并进行DNA倍体和细胞周期各时相比例的分析。结果食管癌、贲门癌和胃癌患者的异倍体率分别为33.3%、60.0%及73.7%;S期增高率分别为36.7%、70.0%及83.6%。腺癌明显高于鳞癌(P<0.05),随病理分级的增高,异倍体率及S期异常率也呈增高趋势。结论三种恶性肿瘤患者DNA倍体的分析,有助于了解肿瘤细胞的增殖情况及恶性程度,可为临床治疗和判断预后提供参考依据。Objective To cvaluatc the clinical value of DNA ploidy of carcinoma of esophagus, gastric cardia and stomach. Methods DNA content of 100 cases with malignant cancer of the upper gastrointestinal tract was measured by flow cytometry. The DNA ploidy and cell cycle distribution was analyzed. Results The DNA aneuploidy of carcinoma of esophagus, gastric cardia and stomach was 33.3% ,60.0% and 73.7% , respectively; the elevated proportion in thc S phase was 36.7% ,70.0% and 83.6%, respectively. The above-mentioned figures were markedly higher in the groups of the adcnocarcinama than squamous carcinoma（ P 〈0.05 ） and the elevated proportion in S phase and DNA aneuploidy tended to increase with the increase of pathological grading. Conclusion DNA ancuploidy of three kinds of malignant cancers is a pertinent index for determining the cell proliferation and malignance.

关 键 词：食管癌 贲门癌 胃癌 DNA 流式细胞术 

分 类 号：R735.1[医药卫生—肿瘤]